New oral drug ICP-248 enters human trials for blood cancers
NCT ID NCT05728658
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 39 times
Summary
This early-stage trial tests an experimental drug called ICP-248, taken as a pill, for people with B-cell blood cancers like leukemia and lymphoma. The study will see if the drug is safe, what dose works best, and whether it helps shrink tumors. About 191 adults aged 18 to 80 are being recruited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Medical University Union Hospital
RECRUITINGFuzhou, Fujian, 350001, China
Contact
-
Hematology Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, 450008, China
Contact
-
Hunan Cancer Hospital
RECRUITINGChangsha, Hunan, 410000, China
Contact
-
Jiangsu Province Hospital
RECRUITINGNanjing, Jiangsu, 210029, China
Contact
-
Jiangxi Cancer Hospital
RECRUITINGNanchang, Jiangxi, 330029, China
Contact
-
Peking University Third Hospital
RECRUITINGBeijing, Beijing Municipality, 100191, China
Contact
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact
-
Shandong cancer hospital
RECRUITINGJinan, Shandong, 250117, China
Contact
-
Shenyang Hospital Of China Medical University
RECRUITINGShenyang, Liaoning, 110022, China
Contact
-
Sun Yat-Sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510062, China
Contact
-
The Central Hospital of Wuhan
RECRUITINGWuhan, Hubei, 430014, China
Contact
-
The First Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, Anhui, 230022, China
Contact
-
The First Affiliated Hospital of Bengbu Medical College
RECRUITINGBengbu, Anhui, 233099, China
Contact
-
The First Affiliated Hospital of Chongqing Medical University
RECRUITINGChongqing, Chongqing Municipality, 400016, China
Contact
-
The First Affiliated Hospital of Nanchang University
RECRUITINGNanchang, Jiangxi, 330000, China
Contact
-
The First Affiliated Hospital of Xiamen University
RECRUITINGXiamen, Fujian, 361003, China
Contact
-
The First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, 450008, China
Contact
-
The Second Hospital of Dalian Medical University
RECRUITINGDalian, Liaoning, 116027, China
Contact
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430022, China
Contact
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610000, China
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ICP-248 (an experimental oral drug) alone or combined with orelabrutinib
What this could lead to
If it works, this could point toward a new treatment option for certain blood cancers like leukemia and lymphoma.
What could go wrong
This is a very early Phase 1 trial with only 191 participants. The drug may not work or could have serious side effects. Success is far from guaranteed.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.